AI in Clinical Trials - Global Strategic Business Report 2026: Secure Share of a US$4.1 Billion Market by 2032 with IQVIA, Microsoft, Tempus AI, and Saama

Yahoo Finance ·

AI in Clinical Trials - Global Strategic Business Report 2026: Secure Share of a US$4.1 Billion Market by 2032 with IQVIA, Microsoft, Tempus AI, and Saama Research and Markets Wed, November 18, 2026 at 10:37 AM EST 5 min read TEM -2.49% MSFT -0.79% Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "AI in Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global artificial intelligence (AI) in clinical trials market was valued at US$1.6 billion in 2025 and is projected to reach US$4.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 14% during the forecast period. Market growth is being supported by rising drug development costs, increasingly complex clinical protocols, demand for personalized therapies, and the pharmaceutical industry's focus on accelerating time to market. AI Is Transforming Clinical Trial Operations AI technologies, including machine learning, natural language processing and predictive analytics, are improving efficiency across patient recruitment, trial design, data management, monitoring and regulatory reporting. By analyzing electronic health records, genetic information and other clinical datasets, AI platforms can identify suitable trial participants more quickly and support the recruitment of broader, more representative patient populations. AI also enables sponsors and contract research organizations to evaluate historical trial data, optimize protocols, select appropriate endpoints and identify high-performing research sites. During active trials, AI-powered platforms can automate data collection, monitor patient responses and flag anomalies in real time. These capabilities support faster decisions, reduce operational delays and help clinical research teams respond more effectively to emerging risks. The increasing complexity of clinical research is a major driver of AI adoption. Precision medicine and personalized treatment development require detailed patient-level data, specialized recruitment strategies and advanced analytical capabilities. AI systems help research organizations manage these requirements while improving the accuracy and efficiency of clinical trial execution. Cost containment is another important market catalyst. Clinical trials account for a substantial share of pharmaceutical research and development spending. AI solutions can automate labor-intensive functions such as site selection, patient matching, data analysis and compliance documentation, allowing sponsors to allocate resources more efficiently and potentially shorten drug development timelines. Demand for real-world evidence is also strengthening the role of AI in observational studies and post-market research. AI platforms can analyze patient registries, insurance claims, electronic health records and other real-world datasets to assess treatment safety, effectiveness and long-term outcomes. Regulatory support for advanced clinical research technologies is expected to further encourage adoption. Improving Clinical Trial Diversity and Accessibility AI is helping address persistent challenges related to clinical trial diversity and patient access. Advanced analytics can combine clinical and sociodemographic data to identify eligible participants from historically underrepresented populations. More inclusive recruitment can improve the relevance of trial results across different demographic groups. AI also supports decentralized and virtual clinical trial models by enabling remote patient monitoring, digital data collection and real-time analysis. These approaches can reduce travel requirements and expand participation among patients in rural or underserved communities. Sponsors can use real-time insights to identify participation barriers, refine recruitment strategies and improve patient retention throughout the trial lifecycle. Application: Drug development, drug discovery, clinical trial management and other applications. End Use: Pharmaceutical and biotechnology companies, academic and research institutes, and other end users. Geographic Coverage: United States, Canada, Japan, China, Europe, Asia-Pacific and the Rest of the World. The software segment is forecast to reach US$2.2 billion by 2032, growing at a CAGR of 13.3%. The services segment is expected to expand at a CAGR of 14.9% over the analysis period. The United States market was valued at US$485.3 million in 2025. China is projected to grow at a CAGR of 13.3% and reach US$706.8 million by 2032, with additional opportunities anticipated across Japan, Canada, Germany and the broader Asia-Pacific region. The report evaluates the competitive environment and profiles companies developing AI software, analytics platforms and clinical research solutions. Featured organizations include: The AI in clinical trials market report provides independent analysis of annual market value and forecasts from 2025 through 2032. It examines market growth, technology adoption, regional performance, competitive positioning and revenue opportunities across major segments. The research also addresses the factors influencing market expansion, potential restraints, expected changes in regional and segment shares, and the outlook for leading industry participants. Purchasers receive detailed market data, regional analysis, company profiles and one year of complimentary report updates. The findings are designed to support pharmaceutical companies, biotechnology organizations, technology providers, investors and research institutions in strategic planning, competitive assessment and opportunity identification. The report incorporates perspectives from domain experts across industry, enterprise and academia, providing context beyond conventional published research. The report tracks early market signals emerging from expert discussions, corporate activity, conference sessions, keynote presentations, panel discussions, company disclosures, annual reports, institutional publications and other validated sources. These insights connect emerging signals with strategic market direction, highlighting the technologies, business models and competitive developments most likely to influence the future of AI-enabled clinical research. Company-level intelligence complements the broader market analysis, while regional market share assessments are included where competitive structures and geographic dynamics require additional detail. With pharmaceutical companies under pressure to improve trial speed, control costs and generate stronger clinical evidence, AI is positioned to become an increasingly important component of drug development. Continued advances in algorithms, data integration, wearable technologies and decentralized trial infrastructure are expected to reinforce the market's growth through 2032. For more information about this report visit https://www.researchandmarkets.com/r/9ulccs About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DYAX Investor Sentiment

Bullish (Long) 36% · Bearish (Short) 64%

427 participants

Related News

원문 보기 — Yahoo Finance